About: C-13-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Aims: The non-invasive 13C-methacetin (13C-MBT) breath test has been proposed as a measure of metabolic liver function that improves the diagnostic efficacy of serologic and biochemical tests in assessing hepatic functional capacity and liver disease severity, The goal of this study was to establish the clinical utility of this test in quantifying hepatic metabolic function in patients with liver cirrhosis of varying severity and to compare 13C-MBT measurements with the AST/ALT ratio, APRI score, and other routine liver tests. Methods: Routine liver function tests including serum bilirubin, aspartate aminotransferase activity (AST), alanine aminotransferase (ALT), AST/ALT ratio, the APRI score, the percentage of dose rate (PDR) and cumulative percentage of dose rate (CPDR) of the 13C-MBT were evaluated in 52 cirrhotic patients of alcohol etiology (Child-Pugh A/B/C 10/28/14) and 37 healthy controls. Results: The 13C-MBT differed significantly between healthy controls and cirrhotic patients at all time intervals measured. It also proved the ability to differentiate patients with liver cirrhosis based on severity of hepatic impairment corresponding to the Child-Pugh classification A vs. B vs. C. The ROC curve analysis suggested that the best prediction is provided by time intervals between the 10th - 20th or 10th - 40th minute of PDR. Conclusions: The 13C-MBT offers a reliable means for quantification of hepatic metabolic function over the complete range of functional liver impairment. It is non-invasive, easy to perform and completely safe.
  • Aims: The non-invasive 13C-methacetin (13C-MBT) breath test has been proposed as a measure of metabolic liver function that improves the diagnostic efficacy of serologic and biochemical tests in assessing hepatic functional capacity and liver disease severity, The goal of this study was to establish the clinical utility of this test in quantifying hepatic metabolic function in patients with liver cirrhosis of varying severity and to compare 13C-MBT measurements with the AST/ALT ratio, APRI score, and other routine liver tests. Methods: Routine liver function tests including serum bilirubin, aspartate aminotransferase activity (AST), alanine aminotransferase (ALT), AST/ALT ratio, the APRI score, the percentage of dose rate (PDR) and cumulative percentage of dose rate (CPDR) of the 13C-MBT were evaluated in 52 cirrhotic patients of alcohol etiology (Child-Pugh A/B/C 10/28/14) and 37 healthy controls. Results: The 13C-MBT differed significantly between healthy controls and cirrhotic patients at all time intervals measured. It also proved the ability to differentiate patients with liver cirrhosis based on severity of hepatic impairment corresponding to the Child-Pugh classification A vs. B vs. C. The ROC curve analysis suggested that the best prediction is provided by time intervals between the 10th - 20th or 10th - 40th minute of PDR. Conclusions: The 13C-MBT offers a reliable means for quantification of hepatic metabolic function over the complete range of functional liver impairment. It is non-invasive, easy to perform and completely safe. (en)
Title
  • C-13-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis
  • C-13-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis (en)
skos:prefLabel
  • C-13-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis
  • C-13-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis (en)
skos:notation
  • RIV/68407700:21460/13:00217378!RIV15-MSM-21460___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • O, P(ED0030/01/01), V
http://linked.open...iv/cisloPeriodika
  • 4
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 67808
http://linked.open...ai/riv/idVysledku
  • RIV/68407700:21460/13:00217378
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • 13C-methacetin breath test; cirrhosis; Child-Pugh classification; non-dispersive infrared spectroscopy; aldehyde dehydrogenase; alcohol dehydrogenase; cytochrome P450; catalase (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • CZ - Česká republika
http://linked.open...ontrolniKodProRIV
  • [40714010FA24]
http://linked.open...i/riv/nazevZdroje
  • Biomedical Papers
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 157
http://linked.open...iv/tvurceVysledku
  • Rosina, Jozef
  • Vránová, Jana
  • Horák, J.
  • Kolářová, H.
  • Krátká, K.
  • Hendrichová, M.
http://linked.open...ain/vavai/riv/wos
  • 000329091500021
issn
  • 1213-8118
number of pages
http://localhost/t...ganizacniJednotka
  • 21460
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 24 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software